Benzene derivative
A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).
1. A method of promoting differentiation of a Schwann cell, comprising contacting a cell with 3-[2-[(E)-5-[3-(benzenesulfonamido)phenyl]pent-4-enoxy]phenyl]propanoic acid or a salt thereof.
2. The method according to claim 1 , wherein the cell is contacted with 3-[2-[(E)-5-[3-(benzenesulfonamido)phenyl]pent-4-enoxy]phenyl]propanoic acid.
3. The method according to claim 1 , wherein the cell is contact with a salt of 3-[2-[(E)-5-[3-(benzenesulfonamido)phenyl]pent-4-enoxy]phenyl]propanoic acid.
4. A method for preventing or treating neuropathy, comprising administering an effective amount of 3-[2-[(E)-5-[3-(benzenesulfonamido)phenyl]pent-4-enoxy]phenyl]propanoic acid or a salt thereof to a mammal.
5. The method according to claim 4 , wherein 3-[2-[(E)-5-[3-(benzenesulfonamido)phenyl]pent-4-enoxy]phenyl]propanoic acid is administered.
6. The method according to claim 4 , wherein a salt of 3-[2-[(E)-5-[3-(benzenesulfonamido)phenyl]pent-4-enoxy]phenyl]propanoic acid is administered.
7. The method according to claim 4 , wherein the neuropathy is a peripheral neuropathy.
8. The method according to claim 7 , wherein the peripheral neuropathy is chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with Charcot-Marie-Tooth disease, peripheral neuropathy associated with an infectious disease, a drug-induced peripheral neuropathy associated with the administration of an anti-convulsant agent, an anti-microbial agent, a chemotherapeutic drug or a sedative agent, multifocal motor neuropathy or a toxic peripheral neuropathy associated with the ingestion of a heavy metal, an organic solvent, a toxic substance or an alcohol.
9. The method according to claim 4 , wherein the mammal is a human.
10. The method according to claim 8 , wherein the drug-induced peripheral neuropathy is peripheral neuropathy associated with the administration of a chemotherapeutic drug.
11. The method according to claim 4 , wherein the neuropathy is central neuropathy.
12. The method according to claim 11 , wherein the central neuropathy is amyotrophic lateral sclerosis.